Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Neoplasms, Breast
Interventions: lapatinib, lapatinib plus esomeprazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Acute Pain
Interventions: Sufentanil, Normal saline, Morphine; Drug
Lead sponsor: The Brooklyn Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Influenza
Interventions: mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Tucson, Arizona • Beverly Hills, California • Plantation, Florida + 5 more

Conditions: Colorectal Adenocarcinoma
Interventions: Quinacrine and Capecitabine; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parent-Child Relations, Child Maltreatment
Interventions: PriCARE/CARIÑO; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Months to 99 Years
Enrollment: 1,932 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Philadelphia, Pennsylvania

Conditions: Blood Pressure
Interventions: Propofol, Ketamine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part Sarcoma
Interventions: Isolated Limb Infusion, Pembrolizumab, infusion of melphalan and dactinomycin; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Acute Pain
Interventions: Placebo, LY3023703, Celecoxib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tumors
Interventions: S-1, FT; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut

Conditions: Hidradenitis Suppurativa, Atopic Dermatitis
Interventions: Lutikizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Sacramento, California • Ann Arbor, Michigan

Conditions: APOL1-mediated Kidney Disease
Interventions: VX-840, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases
Interventions: RO7119929, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Interventions: inupadenant, Placebo, Carboplatin, Pemetrexed; Drug
Lead sponsor: iTeos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Tampa, Florida

Conditions: Asthma
Interventions: Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Chronic Low Back Pain
Interventions: Orthotics, Orthotics Plus Chiropractic Care, Wait List; Other
Lead sponsor: National University of Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lombard, Illinois

Conditions: Barth Syndrome
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioblastoma, Oligodendroglioma, Anaplastic Oligodendroglioma
Interventions: RRx-001 dose escalation with TMZ + RT, Radiation, Fixed dose Temozolomide (75 mg/m2), TMZ Maintenance; Drug · Radiation
Lead sponsor: EpicentRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: San Francisco, California • New Brunswick, New Jersey • New York, New York

Conditions: Locally Advanced/Metastatic Solid Tumors
Interventions: BJ-001, Pembrolizumab; Drug
Lead sponsor: BJ Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: St Louis, Missouri • New York, New York • Greenville, South Carolina + 2 more

Conditions: Multiple Myeloma
Interventions: Dara-RVd, Tec-RVd; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligodendroglioma
Interventions: gefitinib, radiation therapy, pharmacological study, laboratory biomarker analysis; Drug · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Resistant Hypertension
Interventions: Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 41
States / cities: Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more

Conditions: Prostatic Neoplasms
Interventions: JNJ-98768111; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Sarasota, Florida • Grand Rapids, Michigan • New York, New York + 1 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: BIIB091, DRF, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 23
States / cities: Scottsdale, Arizona • Berkeley, California • Orange, California + 20 more

Search by objective public record fields.

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

Intranasal Sufentanil Versus Intravenous Morphine for the Management of Acute Pain

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma

Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)

A Comparison of Ketofol (Ketamine and Propofol Admixture) Versus Propofol as Induction Agents on Hemodynamic Parameters

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal

A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

Orthotic Use for Chronic Low Back Pain

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas

Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)